Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Aardvark Therapeutics Sector: Oral gut-restricted bitter taste receptor agonists for hunger suppression HQ: San Diego, CA Year Founded: 2017 Origin Story: Aardvark Therapeutics was founded around a mechanistically distinct hypothesis: rather than suppressing appetite like GLP-1 drugs, the companys lead compound activates bitter taste receptors (TAS2Rs) confined to the gastrointestinal tract to trigger local release of satiety hormones, targeting hunger itself without systemic drug exposure
Given the increase in childhood obesity and early onset of type 2 diabetes, a focus on this area would have the potential to reduce future morbidity
There were three serious adverse events (two cases of vomiting and one of colitis) that may have been due to liraglutide
By mimicking the GLP-1 hormone, it helps control appetite and reduce food intake by promoting feelings of fullness for longer, which is capable of leading to substantial weight loss
